Castle Biosciences Inc（CSTL）の株式分析CSTLCastle Biosciences Inc

Castle Biosciences, Inc. is a molecular diagnostics company offering test solutions to aid clinicians in the diagnosis and treatment of dermatologic cancers, Barrett’s esophagus (BE), uveal melanoma (UM), and in the treatment of mental health conditions. The Company offers around six commercially available proprietary multi-analyte assays with algorithmic analysis (MAAA) tests for use in the fields of dermatology, gastroenterology ophthalmology and includes a test to guide systemic treatment decisions in patients with moderate-to-severe AD. It also offers a proprietary pharmacogenomic (PGx) test to guide optimal drug treatment for patients diagnosed with depression, anxiety and other mental health conditions. Its products include DecisionDx-Melanoma, DecisionDx-SCC, MyPath Melanoma, TissueCypher, IDgenetix, and DecisionDx-UM. DecisionDx-SCC is its proprietary gene expression profile (GEP) test for patients with cutaneous squamous cell carcinoma (SCC). It operates in the Healthcare sector (SERVICES-MEDICAL LABORATORIES industry).

Castle Biosciences Inc (CSTL) is currently not a strong buy due to its low RSI of 32.804 indicating oversold conditions, but it has a positive revenue growth outlook with Q2 2026 revenue reported at $103.5 million, a 20% increase year-over-year. The main risk is its negative net income of $2.1 million in Q2 2026, which raises concerns about profitability.